APTITUDE HEALTH®

EPICS

Conference Coverage: ASCO and EHA 2024 – Focus on Lymphoma

June 20, 2024

Report Contents

EPICS

Meeting Snapshot

EPICS

EPICS

VIRTUAL CLOSED-DOOR ROUNDTABLE

DATE:
June 20, 2024



DISEASE STATE AND DATA PRESENTATIONS by key experts

INSIGHTS REPORT including postmeeting analyses and actionable recommendations

PANEL: Key experts in lymphoma

- 4 from US
- 3 from Europe

LYMPHOMA-SPECIFIC DISCUSSIONS on therapeutic advances and their application in clinical decision-making

Panel Consisting of 4 US and 3 European Lymphoma Experts

EPICS

Matthew Lunning, DO, FACP
University of Nebraska Medical Center

Paolo Caimi, MD
Cleveland Clinic

P. Connor Johnson, MD
Massachusetts General Hospital

John Gribben, MD
Barts Cancer Institute

CHAIR:
Brad Kahl, MD
Washington University School of Medicine

Georg Hess, MD
University Medical Center Mainz

Pier Luigi Zinzani, MD, PhD
University of Bologna

APTITUDE HEALTH®

Meeting Agenda (1/2)

EPICS

Time (EST/CET)	Topic	Speaker/Moderator
11.00 AM – 11.05 AM/18.00 – 18.05	**Welcome and Introductions**	Brad Kahl, MD
11.05 AM – 11.20 AM/18.05 – 18.20	**Advances in DLBCL/Aggressive B-Cell Lymphoma Excluding CAR T**	Georg Hess, MD
11.20 AM – 11.35 AM/18.20 – 18.35	**Discussion**	Moderator: Brad Kahl, MD All faculty
11.35 AM – 11.40 AM/18.35 – 18.40	**Key Takeaways for Advances in DLBCL/Aggressive B-Cell Lymphoma Excluding CAR T**	Georg Hess, MD
11.40 AM – 11.50 AM/18.40 – 18.50	**Advances in CAR T for NHL/CLL – Clinical Updates**	P. Connor Johnson, MD
11.50 AM – 12.05 PM/18.50 – 19.05	**Discussion**	Moderator: Brad Kahl, MD All faculty
12.05 PM – 12.10 PM/19.05 – 19.10	**Key Takeaways for Advances in CAR T for NHL/CLL – Clinical Updates**	P. Connor Johnson, MD
12.10 PM – 12.25 PM/19.10 – 19.25	**Advances in CAR T for NHL/CLL – Special Questions**	Paolo Caimi, MD
12.25 PM – 12.40 PM/19.25 – 19.40	**Discussion**	Moderator: Brad Kahl, MD All faculty
12.40 PM – 12.45 PM/19.40 – 19.45	**Key Takeaways for Advances in CAR T for NHL/CLL – Special Questions**	Paolo Caimi, MD
12.45 PM – 12.55 PM/19.45 – 19.55	**BREAK**	

Meeting Agenda (2/2)

EPICS

Time (EST/CET)	Topic	Speaker/Moderator
12.55 PM – 1.05 PM/19.55 – 20.05	**Advances in MCL**	Matthew Lunning, DO, FACP
1.05 PM – 1.15 PM/20.05 – 20.15	**Discussion**	Moderator: Brad Kahl, MD All faculty
1.15 PM – 1.20 PM/20.15 – 20.20	**Key Takeaways for Advances in MCL**	Matthew Lunning, DO, FACP
1.20 PM – 1.30 PM/20.20 – 20.30	**Advances in FL and MZL**	Pier Luigi Zinzani, MD, PhD
1.30 PM – 1.45 PM/20.30 – 20.45	**Discussion**	Moderator: Brad Kahl, MD All faculty
1.45 PM – 1.50 PM/20.45 – 20.50	**Key Takeaways for Advances in FL and MZL**	Pier Luigi Zinzani, MD, PhD
1.50 PM – 2.05 PM/20.50 – 21.05	**Evolving Therapies in CLL/SLL**	John Gribben, MD
2.05 PM – 2.20 PM/21.05 – 21.20	**Discussion**	Moderator: Brad Kahl, MD All faculty
2.20 PM – 2.25 PM/21.20 – 21.25	**Key Takeaways for Evolving Therapies in CLL/SLL**	John Gribben, MD
2.25 PM – 2.30 PM/21.25 – 21.30	**Wrap-Up and Close**	Brad Kahl, MD

APTITUDE HEALTH®

EPICS

Conference Highlights

Advances in DLBCL/Aggressive B-Cell Lymphoma Excluding CAR T

ORIENT STUDY: ORELABRUTINIB ADDED TO AN R-CHOP–LIKE REGIMEN SHOWED ACCEPTABLE CLINICAL RESPONSE IN TREATMENT-NAIVE NON-GCB DLBCL

Qu CJ, et al. EHA 2024. Abstract P1167

EPICS

STUDY POPULATION

Clinical responses

GOLCADOMIDE + R-CHOP SHOWED PROMISING EARLY RESULTS WITH TOLERABLE SAFETY IN FRONTLINE AGGRESSIVE BCL

Hoffmann MS, et al. EHA 2024. Abstract S235

EPICS

STUDY POPULATION

Clinical efficacy

TUCIDINOSTAT + R-CHOP IN FRONTLINE DLBCL WITH DOUBLE EXPRESSION OF *MYC* AND *BCL2*: AN INTERIM ANALYSIS FROM THE PHASE III DEB STUDY

Zhao W, et al. ASCO 2024. Abstract LBA7003

EPICS

STUDY POPULATION

Primary endpoint of EFS was met

BRENTUXIMAB VEDOTIN IN COMBINATION WITH R2 IS ACTIVE IN R/R DLBCL: RESULTS FROM THE PHASE III ECHELON-3 STUDY

Kim JA, et al. ASCO 2024. Abstract LBA7005

EPICS

STUDY POPULATION

Primary endpoint of mOS was met

EPCORITAMAB + GEMOX INDUCES DEEP DURABLE RESPONSES IN R/R DLBCL: UPDATES RESULTS FROM EPCORE NHL-2 TRIAL

Cordoba R, et al. EHA 2024. Abstract P1152

EPICS

STUDY POPULATION

Efficacy outcomes, durable CR

GLOFITAMAB-GEMOX SHOWED PROMISING ACTIVITY IN R/R DLBCL: RESULTS OF THE PHASE III STARGLO TRIAL

Abramson J, et al. EHA 2024. Abstract LB3438

EPICS

STUDY POPULATION

Primary endpoint: Updated OS

APTITUDE HEALTH®

EPICS

Key Highlights

Advances in DLBCL/Aggressive B-Cell Lymphoma Excluding CAR T

Advances in DLBCL/Aggressive B-Cell Lymphoma Excluding CAR T (1/2)

EPICS

No practice-changing updates were showcased at ASCO and EHA for frontline DLBCL. However, numerous larger phase III trials are

Advances in DLBCL/Aggressive B-Cell Lymphoma Excluding CAR T (2/2)

EPICS

Combination approaches with bispecifics could reintroduce chemotherapies in the

APTITUDE HEALTH®

EPICS

Conference Highlights

Advances in CAR T for NHL/CLL

7-DAY VEIN-TO-VEIN CAR T DELIVERY IS FEASIBLE WITH DECENTRALIZED MANUFACTURING: RESULTS FROM THE ATALANTA-1 TRIAL

Kersten MJ, et al EHA 2024. Abstract S243

EPICS

STUDY POPULATION

Response over time

AXI-CEL SHOWED DURABLE RESPONSES IN PRIMARY MEDIASTINAL BCL ACCORDING TO AN ANALYSIS FROM THE DESCAR-T REGISTRY

Galtier J, et al. EHA 2024. Abstract S240

EPICS

STUDY POPULATION

OS with axi-cel (n=55)

ENCOURAGING CLINICAL RESPONSE TO LISO-CEL IN R/R CLL INDEPENDENT OF RISK GROUPS AND AGE: EXPLORATORY ANALYSIS OF TRANSCEND CLL 004

Wierda WG, et al. EHA 2024. Abstract S158

EPICS

STUDY POPULATION

Tumor burden correlation with ORR

PET-CT ON DAY 14 IS PREDICTIVE OF METABOLIC RESPONSE IN R/R LBCL; DEAUVILLE SCORE 5 ON DAY 14 CONFERS POOR PROGNOSIS

Al Tabaa Y, et al. EHA 2024. Abstract P1202

EPICS

STUDY POPULATION

Survival outcomes

PIRTOBRUTINIB IN COMBINATION WITH BISPECIFIC CAR T (LV20.19) SEEMS FEASIBLE IN R/R LYMPHOMA

Furqan F, et al. ASCO 2024. Abstract 7043

EPICS

STUDY POPULATION

Efficacy outcomes

CAR T FOR TRANSFORMED LYMPHOMA SEEMS TO BE EFFICACIOUS: A DESCAR-T ANALYSIS

Stephan P, et al. EHA 2024. Abstract S241

EPICS

STUDY POPULATION

PFS

CAR T IS FEASIBLE IN PATIENTS AGED OVER 75 YEARS WITH R/R LBCL: A DESCAR-T REGISTRY ANALYSIS

Guffroy B, et al. EHA 2024. Abstract S242

EPICS

STUDY POPULATION

No significant difference in main outcomes

OUTPATIENT AXI-CEL WITH PROPHYLACTIC STEROIDS IS VIABLE AND RELATIVELY SAFE: PRELIMINARY ANALYSIS OF COHORT 6 IN ZUMA-1 TRIAL

Leslie L, et al. EHA 2024. Abstract P1159

EPICS

STUDY POPULATION

Hospitalization

SECONDARY MALIGNANCIES SEEN IN 5% OF PATIENTS POST-CAR T IN LYMPHOMA: ANALYSIS FROM THE ITALIAN CART-SIE STUDY

Barone A, et al. EHA 2024. Abstract P1156

EPICS

STUDY POPULATION

Secondary malignancies in 28 pts (4.3%)

IBRUTINIB OR VENETOCLAX PRETREATMENT MAY CHANGE SOME T-CELL POPULATIONS IN SUBSEQUENT CAR T THERAPY: PRELIMINARY ANALYSIS OF GIMEMA CLL2020

Griggo V, et al. EHA 2024. Abstract S191

EPICS

STUDY POPULATION

Overview of outcomes

NO SIGNIFICANT SURVIVAL BENEFIT BY ADDING TAFASITAMAB TO LENALIDOMIDE IN POST-CAR T RELAPSE: A LYSA STUDY FROM DESCAR-T REGISTRY

Camus V, eta l. EHA 2024. Abstract P1153

EPICS

STUDY POPULATION

Survival outcomes

ODRONEXTAMAB DEMONSTRATES DURABLE COMPLETE RESPONSES AFTER CAR T RELAPSE IN DLBCL: OUTCOMES FROM THE ELM-1 STUDY

Michot JM, et al. EHA 2024. Abstract P1162

EPICS

STUDY POPULATION

Pt characteristics and responses

APTITUDE HEALTH®

EPICS

Key Highlights

Advances in CAR T for NHL/CLL

Advances in CAR T for NHL/CLL – Clinical Updates (1/3)

EPICS

Advances in CAR T for NHL/CLL – Clinical Updates (2/3)

EPICS

Advances in CAR T for NHL/CLL – Clinical Updates (3/3)

EPICS

Advances in CAR T for NHL/CLL – Specific Questions (1/3)

EPICS

Advances in CAR T for NHL/CLL – Specific Questions (2/3)

EPICS

Post-CAR T secondary primary malignancies are becoming a focus of attention in lymphomas and in other indications

Advances in CAR T for NHL/CLL – Specific Questions (3/3)

EPICS

Dr Pagano

We used to run out of good options and we would just default to the mean of chemotherapy plus trastuzumab in the salvage setting, but now we have so many great choices that that really tends a backseat. It's really been exciting to have multiple options for patients after T-DM1 – again, practice changing, unprecedented

APTITUDE HEALTH®

EPICS

Conference Highlights

Advances in MCL

WATCH-AND-WAIT STRATEGY MAY BE FEASIBLE IN NEWLY DIAGNOSED MCL: PROSPECTIVE ANALYSIS IN UK

Mant S, et al. EHA 2024. Abstract S230

EPICS

STUDY POPULATION

OS outcome

IBRUTINIB + VENETOCLAX SHOWED ENCOURAGING OS IN PATIENTS WITH MCL AND *TP53* MUTATION: ANALYSIS OF THE SYMPATICO TRIAL

Jurczak W, et al. EHA 2024. Abstract 1127

EPICS

STUDY POPULATION

OS with ibrutinib + venetoclax

ACALABRUTINIB + R2 SHOWED IMPROVED PFS IN UNTREATED MCL: RESULTS FROM THE ECHO TRIAL

Wang M, et al. EHA 2024. Abstract LB3439

EPICS

STUDY POPULATION

Primary endpoint of PFS was reached

LISO-CEL SHOWED GOOD CLINICAL ACTIVITY IN MCL IN MORE-PRETREATED PATIENTS: SUBGROUP ANALYSIS OF TRANSCEND NHL 001 MCL COHORT

Kamdar M, et al. EHA 2024. Abstract P1126

EPICS

STUDY POPULATION

Clinical outcomes

GLOFITAMAB MONOTHERAPY DEMONSTRATED DURABLE RESPONSES IN HEAVILY PRETREATED MCL: UPDATED ANALYSIS OF A PHASE I/II TRIAL

Phillips T, et al. EHA 2024. Abstract S231

EPICS

STUDY DESIGN AND POPULATION

OS and CRS outcomes

APTITUDE HEALTH®

EPICS

Key Highlights

Advances in MCL

Advances in MCL (1/2)

EPICS

APTITUDE HEALTH®

Advances in MCL (2/2)

EPICS

Dr Pugnet

We used to run out of good options and we would just regress to the mean of chemotherapy plus rituximab in the salvage setting, but now we have so many great choices that that really tends a backseat. It's really been exciting to have multiple options for patients after [illegible] again, practice changing, unprecedented

APTITUDE HEALTH®

EPICS

Conference Highlights

Advances in Indolent Lymphomas (FL and MZL)

MOSUNETUZUMAB SHOWS DURABLE OUTCOMES IN HIGH-RISK R/R FL: 3-YEAR FOLLOW-UP SUBGROUP ANALYSIS OF PIVOTAL PHASE II TRIAL

Assouline S, et al. EHA 2024. Abstract S233

EPICS

STUDY POPULATION

Clinical efficacy across high-risk subgroups

RESPONSE-ADAPTED MOSUNETUZUMAB ± OBINUTUZUMAB + POLATUZUMAB VEDOTIN SEEMS FEASIBLE IN NEWLY DIAGNOSED FL: INTERIM ANALYSIS OF PHASED-SEQ MRD ANALYSIS

Lynch R, et al. EHA 2024. Abstract P1127

EPICS

STUDY OVERVIEW

[redacted]

Mosunetuzumab responses and safety

[redacted]

[redacted]

ATEZOLIZUMAB + OBINUTUZUMAB ± RT REACHED HIGH MOLECULAR RESPONSE RATE IN FRONTLINE FL: RESULTS FROM THE FLUORO TRIAL

Chong G, et al. ASCO 2024. Abstract 7070

EPICS

STUDY POPULATION

Pt characteristics and efficacy overview

ODRONEXTAMAB SHOWED DURABLE RESPONSES, ESPECIALLY FOR PATIENTS IN CR IN R/R FL: PRIMARY ANALYSIS OF ELM-2 STUDY

Taszner M, et al. EHA 2024. Abstract S232

EPICS

STUDY OVERVIEW

[redacted]

OS outcomes

[redacted]

[redacted]

SUBCUTANEOUS EPCORITAMAB SHOWED DURABLE CLINICAL RESPONSES IN R/R FL: AN INDIRECT COMPARISON WITH SCHOLAR-5 STANDARD OF CARE

Sureda Balari A, et al. EHA 2024. Abstract P1140

EPICS

STUDY POPULATION

Survival outcomes



EPCORITAMAB ± R2 SHOWED FAVORABLE RESPONSES AND SAFETY IN FRONTLINE FL: RESULTS FROM EPCORE NHL-2 ARMS 6 AND 7

Falchi L, et al. EHA 2024. Abstract P1146

EPICS

STUDY OVERVIEW

[redacted]

Response in arm 6 (epcoritamab + R2)

[redacted]

APTITUDE HEALTH®

EPICS

Key Highlights

Advances in Indolent Lymphomas (FL and MZL)

Advances in Indolent Lymphomas (FL and MZL) (1/3)

EPICS

APTITUDE HEALTH®

Advances in Indolent Lymphomas (FL and MZL) (2/3)

EPICS

Dr Pagano

We used to run out of good options and we would just regress to the mean of chemotherapy plus rituximab in the salvage setting, but now we have so many great choices that that really tends a backseat. It's really been exciting to have multiple options for patients after [redacted] again, practice changing, unprecedented

APTITUDE HEALTH®

Advances in Indolent Lymphomas (FL and MZL) (3/3)

EPICS

APTITUDE HEALTH®

EPICS

Conference Highlights

Advances in CLL

COMPREHENSIVE LANDSCAPE ANALYSIS REVEALED ADVERSE PROGNOSTIC ROLE OF *TP53* MUTATIONS IN CLL

Bertossi C, et al. EHA 2024. Abstract S101

EPICS

STUDY POPULATION

Prognostic impact of *TP53* mutation and del(17p)

ZANUBRUTINIB + VENETOCLAX SHOWED DURABLE RESPONSES IN DEL(17P)/*TP53*-MUTATED CLL: RESULTS FROM ARM D IN SEQUOIA TRIAL

Ghia P, et al. EHA 2024. Abstract S160

EPICS

STUDY DESIGN AND POPULATION

Initial zanubrutinib reduced the risk for TLS

A NETWORK META-ANALYSIS OF HEAD-TO-HEAD TRIALS SHOWED DIFFERENCES IN BTKI ACTIVITY FOR PATIENTS WITH DEL(17)/*TP53* MUTATION

Shadman M, et al. EHA 2024. Abstract P700

EPICS

STUDY POPULATION

Prognostic impact of *TP53* mutation and del(17p)

PIRTOBRUTINIB + VENETOCLAX + OBINUTUZUMAB SHOWED HIGH UMRD RATES IN FRONTLINE CLL

Jain N, et al. EHA 2024. Abstract S164

EPICS

STUDY POPULATION

Initial pirtobrutinib reduced the risk for TLS

MRD-ADAPTED, TIME-LIMITED ACALABRUTINIB + OBINUTUZUMAB MAINTAINED UMRD 3 MONTHS AFTER TREATMENT COMPLETION IN CLL

Roeker L, et al. EHA 2024. Abstract P672

EPICS

STUDY POPULATION

MRD levels during and after therapy



ORELABRUTINIB IN COMBINATION WITH CHEMOTHERAPY AND OBINUTUZUMAB DEMONSTRATED DEEP MRD IN FRONTLINE CLL

Zhu H, et al. EHA 2024. Abstract P680

EPICS

STUDY POPULATION

Trial design and MRD levels during treatment

ACALABRUTINIB DISCONTINUATION HAD A DISMAL EFFECT ON SURVIVAL IN CLL

Tedeschi A, et al. EHA 2024. Abstract P691

EPICS

STUDY POPULATION

OS according to dose groups

APTITUDE HEALTH®

EPICS

Key Highlights

Advances in CLL

Advances in CLL

EPICS

Dr Pagano

We used to run out of good options and we would just default to the mean of chemotherapy plus trastuzumab in the salvage setting, but now we have so many great choices that that really takes a backseat. It's really been exciting to have multiple options for patients after T-DXd — again, practice changing, unprecedented

APTITUDE HEALTH®

US 5901-B Peachtree Dunwoody Road
Suite 415, Atlanta, GA 30328, US

EU Laan van Nieuw Oost-Indië 133 F
2593 BM The Hague, the Netherlands

UK 6th Floor, 2 Kingdom Street
London, W2 6BD, United Kingdom

aptitudehealth.com